Kelly Financial Services LLC Editas Medicine, Inc. Transaction History

Kelly Financial Services LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Jul 17, 2024	SELL	$39.27 - $72.94 $3.57 Million - $6.63 Million	-90,860 Reduced 98.23%	1,633 $67.1 Million
Q2 2021 Jul 17, 2024	BUY	$31.29 - $56.64 $2.84 Million - $5.15 Million	90,860 Added 5563.99%	92,493 $1.63 Million
Q3 2019 Jul 17, 2024	SELL	$22.49 - $26.81 $1,574 - $1,876	-70 Reduced 4.11%	1,633 $37.1 Million
Q1 2019 Jul 17, 2024	BUY	$19.43 - $26.41 $33,089 - $44,976	1,703 New	1,703 $41.6 Million

242

58.7M

494K

417K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $214M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Kelly Financial Services LLC, based on Form 13F filings with the SEC.

Stay updated on Kelly Financial Services LLC with notifications on news.